A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

This Phase 1/2 study (RESET-PV) tests two CAR T-cell therapies for pemphigus vulgaris (PV) — a rare and potentially life-threatening autoimmune disease where the immune system attacks proteins that hold skin cells together, causing painful blistering on the skin and mucous membranes. Standard treatments rely on long-term immunosuppression, which carries significant risks. This trial engineers the patient's own immune cells to seek out and eliminate only the specific immune cells causing the disease. The study is currently focused on CABA-201, a CD19-targeted CAR T-cell therapy. Patients donate their own T-cells, which are genetically modified in a lab and then infused back into the body. This personalized 'living drug' is designed to reset the immune system and potentially put PV into long-term remission without lifelong immunosuppression. You may be eligible if: - You are 18 years of age or older - You have a confirmed diagnosis of pemphigus vulgaris (PV) by biopsy and positive antibody testing - Your PV is inadequately controlled by at least one standard immunosuppressive therapy - You have active PV at the time of screening You may NOT be eligible if: - You have paraneoplastic pemphigus or active malignancy (diagnosed within the last 5 years) - You have received rituximab or other anti-CD19/CD20 therapy in the last 12 months - You are taking prednisone at a dose above 0.25 mg/kg/day - You have another autoimmune disorder requiring immunosuppressive therapy - You received any investigational treatment within the past 4 weeks Talk to your doctor to see if this trial is right for you.